Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2024-04-04 AGM Information
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Notice of Annual General Meeting of Medivir AB (publ)
AGM Information Classification · 99% confidence The document is explicitly titled "Notice of Annual General Meeting of Medivir AB (publ)" and details the date, time, location, procedures for participation (in person or advance voting), shareholder rights, proposed agenda items (including election of directors, approval of financial statements, and remuneration guidelines), and specific proposals related to the meeting. This content directly corresponds to the materials distributed to shareholders in preparation for an Annual General Meeting (AGM). Although it mentions the remuneration report (Item 18) and guidelines (Item 17), the primary purpose and structure of the document is the formal summons and information package for the AGM itself. Therefore, the most appropriate classification is AGM-R (AGM Information).
2024-04-04 English
Kallelse till årsstämma i Medivir AB (publ)
AGM Information Classification · 100% confidence The document is titled "Kallelse till årsstämma i Medivir AB (publ)" which translates to "Notice of Annual General Meeting in Medivir AB (publ)". The text details the date, time, location, procedures for participation (in person or by advance voting), registration deadlines, and the proposed agenda for the meeting. The agenda items explicitly cover elections (board members, chairman, auditor), approval of financial statements, dividend disposition, and remuneration guidelines, all standard components of an AGM notice. This clearly identifies the document as materials related to the Annual General Meeting. Based on the definitions, the appropriate code is AGM-R (AGM Information).
2024-04-04 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 95% confidence The document is a 'Bokslutskommuniké' (Year-end report) for Medivir AB covering the period January to December 2023. It contains comprehensive financial summaries (income statements, cash flow, liquidity), detailed management commentary on business performance, clinical trial updates, and future outlook. As it covers a full fiscal year and provides substantive financial data and analysis, it is classified as an Interim/Quarterly Report (IR) in the context of the provided filing categories, as it serves as the final quarterly/periodical report for the fiscal year. FY 2023
2024-02-15 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is a 'Year-End Report' for Medivir AB covering the period January to December 2023. It contains detailed financial summaries (turnover, EBITDA, earnings per share, cash flow), significant events, CEO's message, and detailed operational updates on clinical trials. Since it covers a period shorter than a full fiscal year (or is the final quarterly/interim report of the year) and contains substantive financial statements and analysis, it is classified as an Interim/Quarterly Report. FY 2023
2024-02-15 English
Number of shares and votes in Medivir AB on 31 January 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly announces the 'Number of shares and votes' as of a specific date (31 January 2024), detailing changes due to a rights issue and a directed issue. This directly relates to the company's capital structure and share count. This content aligns best with the 'Share Issue/Capital Change' category (SHA), as it reports the final resulting share count after recent capital activities. It is not a general earnings release (ER), a dividend notice (DIV), or a director's dealing report (DIRS). The document is short and appears to be a press release announcing a change in the total number of shares, fitting the SHA definition.
2024-01-31 English
Antalet aktier och röster i Medivir AB per den 31 januari 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a short announcement from Medivir AB, dated around the end of January 2024, detailing the change in the total number of shares and votes following recent share issues (a rights issue and a directed issue). This type of announcement, which reports on changes in the capital structure due to new share issuance, directly corresponds to the 'Share Issue/Capital Change' definition. The document is brief and appears to be a press release announcing a change in share count, fitting the 'SHA' code better than a general 'RNS' or a specific financing event like 'CAP' (which usually implies fundraising terms).
2024-01-31 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.